PFAS Becomes the Next Asbestos
Enforceable drinking-water limits are forcing utilities and industrial users to spend on testing, filtration and remediation. Treatment vendors gain a long-duration installed base, while historical PFAS producers face settlements, legal costs and uncertain residual liabilities. The market is increasingly treating PFAS exposure as a balance-sheet issue rather than a routine environmental expense.
How this story could end...
The endings this story genuinely supports, written from the same evidence as the story updates. The value ranges are illustrative examples of how the affected companies as a group could re-rate — not forecasts, targets or advice.
Mapping out the endings…
How the two sides have traded
The bull and bear baskets for this story, equal-weighted and indexed so the two lines start together.
Each scenario's basket — 3 months
Both sides on one chart — 5 stocks on the bull side, 4 stocks on the bear side. The bear line is emphasised.
Each line tracks the 10 companies most exposed to this story, so a broad basket of loosely related names does not flatten it. The full list below is unchanged.
Jul 21, 2026 – Oct 19, 2026 · 60 sessions
Equal-weighted performance of the 10 most exposed stocks over the last 3 months.
Most affected stocks
Bear case
Legacy DuPont liabilities leave Corteva sharing costs despite PFAS being outside its core agricultural business.
Chemours has particularly concentrated exposure to fluorochemical cleanup obligations and related litigation.
Legacy PFAS production leaves 3M exposed to settlement payments, remediation costs and additional claims.
Historical chemical operations create continuing PFAS litigation and indemnification uncertainty.
Reporting behind this story
Looking at what moved this story…